Why the study?
Does acenocoumarol reduce bone density in women with cardiac valve replacement compared to age-matched controls?
Does acenocoumarol reduce bone density in women with cardiac valve replacement compared to age-matched controls?
Answers are grounded in this paper and cite their sources.
Oral anticoagulant therapy with acenocoumarol is associated with significantly reduced appendicular bone density and osteopenia in adult women.
Recent literature indicates that the vitamin K cycle plays a role in the calcification process, presumably via its intervention on gamma-carboxylation of the noncollagenous proteins of bone osteocalcin and matrix gamma-carboxyglutamic acid protein. The major clinical evidence of this interference is fetal bone defect caused by oral anticoagulants given to the mother during the first trimester of pregnancy. No bone abnormalities have been reported so far in adults receiving oral anticoagulants. We studied 56 women who had had cardiac valve replacement and who were given acenocoumarol as anticoagulant, and 61 age-matched women who were in the same New York Heart Association functional class but who were not taking anticoagulants. Osteocalcin serum levels were comparable between the two groups; bone density values measured at appendicular bone were significantly lower in patients taking acenocoumarol. No significant correlation was found between duration of treatment and bone density. Significant osteopenia was present in the women being treated with oral anticoagulants.
No takes yet. Share an insight, caveat, or question.
Fiore et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: